Evidence-based imaging in lung cancer: A systematic review

Journal of Thoracic Imaging

Volumn 27, Issue 5, 2012, Pages 315-324

  Ravenel, James G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

computed tomography; lung cancer; positron emission tomography computed tomography; staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TOBACCO SMOKE;

ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED IMAGING; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HISTOLOGY; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG SMALL CELL CANCER; MEDICAL TECHNOLOGY; MEDICARE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RADIOLOGIST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; WHOLE BODY PET;

BIOPSY; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SMALL CELL LUNG CARCINOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84865776322     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e318254a198     Document Type: Article

References (85)

1. Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health. 1978;32: 303-313. (Pubitemid 9067838)
2. Tong L, Spitz MR, Fueger JJ, et al. Lung carcinoma in former smokers. Cancer. 1996;78:1004-1010. (Pubitemid 26284865)
3. Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med. 1955;12:81-86.
4. Preston DL, Shimizu Y, Pierce DA, et al. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiation Res. 2003; 160:381-407. (Pubitemid 37174507)
5. Dockery DW, Pope CA III, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl J Med. 1993;329:1753-1759. (Pubitemid 23355547)
6. Wraith D, Mengersen K. Assessing the combined effect of asbestos exposure and smoking on lung cancer: a Bayesian approach. Stat Med. 2007;26:1150-1169. (Pubitemid 46291137)
7. Pierce DA, Sharp GB, Mabuchi K. Joint effects of radiation and smoking on lung cancer risk among atomic bomb survivors. Radiation Res. 2003;159:511-520. (Pubitemid 36397773)
8. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease and Prevention and Health Promotion, Office of Smoking and Health; 2006.
9. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
10. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control. 2006;15:345-347. (Pubitemid 44606728)
11. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer. 2005;93:825-833. (Pubitemid 41486445)
12. Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-1999. Morb Mortal Wkly Rep. 2002;51:300-303.
13. Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the United States: estimates, their validity, and their implications. Tob Control. 1999;8:290-300.
14. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630-641.
15. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50:143-154. (Pubitemid 41427890)
16. Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res. 2011;11:305.
17. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:324S-339SS.
18. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132: 178S-201S. (Pubitemid 47502807)
19. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:108S-1030S.
20. Mountain C. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717. (Pubitemid 27260107)
21. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997;157:849-855. (Pubitemid 28337035)
22. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology. 2009;253:606-622.
23. Pearlberg JL, Sandler MA, Beute GH, et al. Limitations of CT in evaluation of neoplasms involving chest wall. J Comput Assist Tomogr. 1987;11:290-293. (Pubitemid 17038156)
24. Pennes DR, Glazer GM, Wimbish KJ, et al. Chest wall invasion by lung cancer: limitations of CT evaluation. Am J Roentgenol. 1985;144:507-511. (Pubitemid 15131006)
25. Glazer HS, Duncan-Meyer J, Aronberg DJ, et al. Pleural and chest wall invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1985;157:191-194. (Pubitemid 16216355)
26. Higashino T, Ohno Y, Takenaka D, et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol. 2005;56:48-55. (Pubitemid 41316486)
27. Bruzzi JF, Komaki R, Walsh GL, et al. Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging and assessment of resectability and therapeutic response. Radiographics. 2008;28:561-572.
28. Glazer GM, Gross BH, Quint LE, et al. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol. 1985;144:261-265. (Pubitemid 15168325)
29. de Langen AJ, Raijmakers P, Riphagen I, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006;29:26-29. (Pubitemid 41831343)
30. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Int Med. 2003;139:879-892.
31. van Tinteren H, Hoekstra O, Smit E, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS Multicentre. Randomised Trial. Lancet. 2002;359: 1388-1393.
32. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group. Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943-1951. (Pubitemid 38020756)
33. Kozower BD, Meyers BF, Reed CE, et al. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg. 2008;85:1166-1169; discussion 9-70.
34. Lee PC, Port JL, Korst RJ, et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:177-181. (Pubitemid 46921151)
35. Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest. 2006;130:1791-1795. (Pubitemid 46033435)
36. Hishida T, Yoshida J, Nishimura M, et al. Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer. Thorax. 2008;63:526-531. (Pubitemid 351831164)
37. Bryant AS, Cerfolio RJ. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucosepositron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers. J Thorac Cardiovasc Surg. 2006;132:1363-1368. (Pubitemid 44820209)
38. Silvestri G, Littenberg B, Colice G. The clinical evaluation for detecting metastatic lung cancer: a meta-analysis. Am J Respir Crit Care Med. 1995;152:225-230.
39. Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest. 2003;123:147S-156S. (Pubitemid 36135712)
40. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235-250. (Pubitemid 351303104)
41. Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. Am J Roentgenol. 2000;175:245-249. (Pubitemid 30415572)
42. Gupta NC, Rogers JS, Graeber GM, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918-1924. (Pubitemid 36051125)
43. Erasmus J, Patz E Jr, McAdams H, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18Ffluorodeoxyglucose positron emission tomography. Am J Roentgenol. 1997;168:1357-1360.
44. Gupta NC, Graeber GM, Tamim WJ, et al. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer. 2001;3:59-64. (Pubitemid 32904317)
45. Vikram R, Yeung HD, Macapinlac HA, et al. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. Am J Roentgenol. 2008;191:1545-1551.
46. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795-1799. (Pubitemid 34016347)
47. Kagohashi K, Satoh H, Ishikawa H, et al. Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol. 2003;20:25-28. (Pubitemid 36344022)
48. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-515; discussion 5-6.
49. Cheran SK, Herndon JE II, Patz EF Jr. Comparison of wholebody FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004;44:317-325. (Pubitemid 38609440)
50. Gayed I, Vu T, Johnson M, et al. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol. 2003;5:26-31. (Pubitemid 36596542)
51. Hsia TC, Shen YY, Yen RF, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma. 2002;49:267-271.
52. Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242:882-888.
53. Mintz BJ, Turhim S, Alexander S, et al. Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest. 1984;86:850-853. (Pubitemid 15181410)
54. Cao JQ, Rodrigues GB, Louie AV, et al. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non-small-cell lung cancer and management of solitary pulmonary nodules. Clin Lung Cancer. 2012;13:161-170.
55. Rice D, Kim HW, Sabichi A, et al. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003;76:1001-1007; discussion 7-8.
56. Lamont JP, Kakuda JT, Smith D, et al. Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA. Arch Surg. 2002;137:935-938; discussion 8-40.
57. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 2.2012. 2012.
58. Korst RJ, Gold HT, Kent MS, et al. Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg. 2005;129:652-660. (Pubitemid 40311327)
59. Cho S, Lee EB. A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg. 2010;139:1447-1451.
60. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg. 2003;125:938-944. (Pubitemid 36457517)
61. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002;73:259-264; discussion 64-66.
62. Port JL, KentMS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg. 2004;77:254-259. (Pubitemid 38130021)
63. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol. 1998;9:1193-1198. (Pubitemid 28552808)
64. Benamore R, Shepherd FA, Leighl N, et al. Does intensive follow-up alter outcome in patients with advanced lung cancer? J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer. 2007;2:273-281. (Pubitemid 47181708)
65. Hopper KD, Kasales CJ, Van Slyke MA, et al. Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol. 1996;167:851-854. (Pubitemid 26322230)
66. Truong MT, Erasmus JJ, Gladish GW, et al. Anatomy of pericardial recesses on multidetector CT: implications for oncologic imaging. Am J Roentgenol. 2003;181:1109-1113. (Pubitemid 37151799)
67. Shankar LK, Van den Abbeele A, Yap J, et al. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009;15:1891-1897.
68. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50(suppl 1):31S-42S.
69. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007; 48:1592-1598. (Pubitemid 47572705)
70. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292. (Pubitemid 46606405)
71. Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 2005;49:95-108. (Pubitemid 40798098)
72. Nahmias C, Hanna WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med. 2007;48:744-751. (Pubitemid 47604974)
73. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657. (Pubitemid 46606307)
74. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J NuclMed. 2009;50(suppl 1):122S-150SS.
75. KentMS, Korn P, Port JL, et al. Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model. Ann Thorac Surg. 2005;80:1215-1222; discussion 22-23.
76. Inoue M, Miyoshi S, Yasumitsu T, et al. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. Ann Thorac Surg. 2000;70:1615-1619.
77. Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer. 2009;4:1049-1059.
78. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366:1385-1396. (Pubitemid 41443406)
79. Hirsch FR, Paulson OB, Hansen HH, et al. Intracranial metastases in small cell carcinoma of the lung. Prognostic aspects. Cancer. 1983;51:529-533. (Pubitemid 13185385)
80. Giannone L, Johnson DH, Hande KR, et al. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med. 1987;106:386-389. (Pubitemid 17029490)
81. Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDGPET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol. 2010;12: 443-451.
82. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 2007;57:328-333. (Pubitemid 47285426)
83. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338-345. (Pubitemid 46323103)
84. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDGPET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614-1620. (Pubitemid 40104607)
85. Bradley JD, Dehdashti F,Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248-3254. (Pubitemid 41103679)